Alexandra Zeltsi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra Zeltsi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amy Rogers
MEMO Research, Division of Cardiovascular Research, Faculty of Health, University of Dundee, Dundee, Scotland, UK
2 shared publications - Ioulietta Lazarou
Information Technologies Institute, Centre for Research and Technology Hellas, CERTH-ITI, 6th km Charilaou-Thermi Road, 57001 Thessaloniki, Greece
2 shared publications - Isla S. Mackenzie
MEMO Research, Division of Cardiovascular Research, Faculty of Health, University of Dundee, Dundee, Scotland, UK
2 shared publications - Lampros Mpaltadoros
Centre for Research and Technology Hellas (CERTH) Information Technologies Institute (ITI) Thessaloniki Greece
2 shared publications - Rachel Copland
MEMO Research, Division of Cardiovascular Research, Faculty of Health, University of Dundee, Dundee, Scotland, UK
2 shared publications - Spiros Nikolopoulos
Multimedia Knowledge and Social Media Analytics Laboratory, Information Technologies Institute, Centre for Research and Technology Hellas, 57001 Thessaloniki, Greece
2 shared publications
Latest Publications
- 20 September 2024
- Published by Springer Nature
- p. 341-351
Intelligent Conversational Agent for Medical Information
- 20 September 2024
- Published by Springer Nature
- p. 341-351
Intelligent Conversational Agent for Medical Information
- Open Access
- 3 September 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26 (1) , e47882
The Digital Platform and Its Emerging Role in Decentralized Clinical Trials
Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools to support trial activities and streamline trial processes. In particular, digital platforms with a modular architecture lend themselves to DCTs, where individual trial activities can correspond to specific platform modules. While design features can allow users to customize their platform experience, the real strengths of digital platforms for DCTs are enabling centralized data capture and remote monitoring of trial participants and in using digital technologies to streamline workflows and improve trial management. When selecting a platform for use in a DCT, sponsors and investigators must consider the specific trial requirements. All digital platforms are limited in their functionality and technical capabilities. Integrating additional functional modules into a central platform may solve these challenges, but few commercial platforms are open to integrating third-party components. The lack of common data standardization protocols for clinical trials will likely limit the development of one-size-fits-all digital platforms for DCTs. This viewpoint summarizes the current role of digital platforms in supporting decentralized trial activities, including a discussion of the potential benefits and challenges of digital platforms for investigators and participants. We will highlight the role of the digital platform in the development of DCTs and emphasize where existing technology is functionally limiting. Finally, we will discuss the concept of the ideal fully integrated and unified DCT and the obstacles developers must address before it can be realized.
- 3 September 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26 (1) , e47882
Open AccessThe Digital Platform and Its Emerging Role in Decentralized Clinical Trials
Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools to support trial activities and streamline trial processes. In particular, digital platforms with a modular architecture lend themselves to DCTs, where individual trial activities can correspond to specific platform modules. While design features can allow users to customize their platform experience, the real strengths of digital platforms for DCTs are enabling centralized data capture and remote monitoring of trial participants and in using digital technologies to streamline workflows and improve trial management. When selecting a platform for use in a DCT, sponsors and investigators must consider the specific trial requirements. All digital platforms are limited in their functionality and technical capabilities. Integrating additional functional modules into a central platform may solve these challenges, but few commercial platforms are open to integrating third-party components. The lack of common data standardization protocols for clinical trials will likely limit the development of one-size-fits-all digital platforms for DCTs. This viewpoint summarizes the current role of digital platforms in supporting decentralized trial activities, including a discussion of the potential benefits and challenges of digital platforms for investigators and participants. We will highlight the role of the digital platform in the development of DCTs and emphasize where existing technology is functionally limiting. Finally, we will discuss the concept of the ideal fully integrated and unified DCT and the obstacles developers must address before it can be realized.
- Open Access
- 6 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The Digital Platform and Its Emerging Role in Decentralized Clinical Trials (Preprint)
UNSTRUCTURED Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools to support trial activities and streamline trial processes. In particular, digital platforms with a modular architecture lend themselves to DCTs, where individual trial activities can correspond to specific platform modules. While design features can allow users to customize their platform experience, the real strengths of digital platforms for DCTs are enabling centralized data capture and remote monitoring of trial participants and in using digital technologies to streamline workflows and improve trial management. When selecting a platform for use in a DCT, sponsors and investigators must consider the specific trial requirements. All digital platforms are limited in their functionality and technical capabilities. Integrating additional functional modules into a central platform may solve these challenges, but few commercial platforms are open to integrating third-party components. The lack of common data standardization protocols for clinical trials will likely limit the development of one-size-fits-all digital platforms for DCTs. This viewpoint summarizes the current role of digital platforms in supporting decentralized trial activities, including a discussion of the potential benefits and challenges of digital platforms for investigators and participants. We will highlight the role of the digital platform in the development of DCTs and emphasize where existing technology is functionally limiting. Finally, we will discuss the concept of the ideal fully integrated and unified DCT and the obstacles developers must address before it can be realized.
- 6 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Digital Platform and Its Emerging Role in Decentralized Clinical Trials (Preprint)
UNSTRUCTURED Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools to support trial activities and streamline trial processes. In particular, digital platforms with a modular architecture lend themselves to DCTs, where individual trial activities can correspond to specific platform modules. While design features can allow users to customize their platform experience, the real strengths of digital platforms for DCTs are enabling centralized data capture and remote monitoring of trial participants and in using digital technologies to streamline workflows and improve trial management. When selecting a platform for use in a DCT, sponsors and investigators must consider the specific trial requirements. All digital platforms are limited in their functionality and technical capabilities. Integrating additional functional modules into a central platform may solve these challenges, but few commercial platforms are open to integrating third-party components. The lack of common data standardization protocols for clinical trials will likely limit the development of one-size-fits-all digital platforms for DCTs. This viewpoint summarizes the current role of digital platforms in supporting decentralized trial activities, including a discussion of the potential benefits and challenges of digital platforms for investigators and participants. We will highlight the role of the digital platform in the development of DCTs and emphasize where existing technology is functionally limiting. Finally, we will discuss the concept of the ideal fully integrated and unified DCT and the obstacles developers must address before it can be realized.